Flagship Biotech International Pvt. Ltd. is one of the leading Generic and Specialty Pharmaceutical companies of India. As a Manufacturer and Exporter, we are actively involved into Manufacturing, Developing and Marketing a wide array of Pharmaceutical Formulations. Our product range includes a broad range of medicines starting from Antiviral Medicines to Cardiovascular Medicines, ENT Medicines, Gastrointestinal Medicines, Hormonal Medicines, Infertility Medicines and many more. We have formulated over 700 pharmaceutical formulations that can be taken in different forms such as Capsules, Ointment, Injections, Inhalers, Creams, Tablets, Dry Powder, etc. Our organization currently serves in more than 75 countries across the globe and has more than 400 products registered to our name. We are dedicated to improving the healthcare sector by providing highly effective medicines and support the masses with our medicinal products. Our company has successfully gained the support of clients with our ability to fulfill their exact requirements.
Board of Directors
Our organization is guided by a visionary board of directors who are highly accomplished in their respective fields and provide their industry expertise to us. The panel is comprised of the following members:
Mr. Shailesh Patel (Promoter & Director): Our Company was founded by Mr. Shailesh Patel, in the year 2009. He is the Promoter and Director of our company and has more than 15 years of experience in the medical domain. Mr. Patel is a well-qualified person with a Bachelor Degree in Pharmacy from SP University and MBA from University of Pondicherry. It is because of his persistence, we have turned into a major player in the medical industry in the national and international markets.
Mr. Kedar Vidwans (Promoter & Director): His contribution in establishing the presence of our company in international markets have been outstanding. He holds a B.E in Chemical, MBA in Marketing and with an experience of more than 10 years, he has helped in formulating various strategic plans that have resulted in the growth of the company. Mr. Vidwans has previously worked with CLARIS Lifescience limited(Ahmedabad) and Wockhardt (Mexico)
Mr. Jesuwin Cherian (Promoter & Director): With more than 16 years of global experience in the international markets of pharmaceutical industry, he has gained the required expertise that has helped us to carve a niche for ourselves among our competitors. He has worked previously with a an esteemed Pharmaceutical Company, Wockhardt and holds a post graduation degree. Mr. Cherian has a crucial role in the marketing function and development of our company's global strategic partnerships
Corporate Social Responsibility
Flagship CSR Policy: Our organization is dedicated to improve the quality of lives of people all around the world. The corporate philosophy we follow, guides us to work together for a common good. The initiatives under our CSR aims at:
- Delivering a positive effect on the society through the Education aid and Medical Aid.
- Improvement of healthcare capacity to serve the community
- Significant investments to fulfill our duties towards the society
Flagship Foundation: We have undertaken two social projects - Education Aid (Gyaan Jyoti) and Medical Aid (Swasthya sparsh). Gyaan Jyoti was founded in the year 2015 to provide education to the needy and unprivileged by sponsoring various educational activities and skill development programs for poor rural and urban youth. Swasthya Sparsh was established with an aim to tackle the health problems of our countrymen. It undertakes initiative programs such as setting up of drinking water huts, Blood donation camps, eye check-up camps in villages and offices and many other.
"We are inviting inquiries only from South America, Africa, Middle East, Cih, South East Asia"
protected under valid patents are not offered or supplied for
commercial use. However, the research quantities of such products may be
offered for the purpose of regulatory submissions, wherever such
regulatory exemptions exist. The buyers should make their independent
evaluation of the patent scenario for their respective markets and will
be responsible for all patent related liabilities.